272 related articles for article (PubMed ID: 10834424)
1. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.
Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R
Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002
[TBL] [Abstract][Full Text] [Related]
5. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
6. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
7. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA
Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
9. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture.
Weyer C; Heise T; Heinemann L
Diabetes Care; 1997 Oct; 20(10):1612-4. PubMed ID: 9314644
[TBL] [Abstract][Full Text] [Related]
10. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
11. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
12. Glucodynamics and pharmacokinetics of 70/30 vs. 50/50 NPH/regular insulin mixtures after subcutaneous injection.
Krug EI; DeRiso L; Tedesco MB; Rao H; Korytkowski MT
Diabetes Care; 2001 Sep; 24(9):1694-5. PubMed ID: 11522727
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
[TBL] [Abstract][Full Text] [Related]
14. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes.
Luzio S; Dunseath G; Peter R; Pauvaday V; Owens DR
Diabetologia; 2006 Jun; 49(6):1163-8. PubMed ID: 16596358
[TBL] [Abstract][Full Text] [Related]
16. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304.
Heinemann L; Sinha K; Weyer C; Loftager M; Hirschberger S; Heise T
Diabet Med; 1999 Apr; 16(4):332-8. PubMed ID: 10220208
[TBL] [Abstract][Full Text] [Related]
17. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
[TBL] [Abstract][Full Text] [Related]
18. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
[TBL] [Abstract][Full Text] [Related]
20. Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.
Rave K; Nosek L; Heinemann L; Frick A; Becker R
Diabetes Metab; 2003 Sep; 29(4 Pt 1):430-1. PubMed ID: 14526272
[No Abstract] [Full Text] [Related]
[Next] [New Search]
